Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Cates S, Santiago OJ, Hersey J, Blitstein J, Kosa K, Singh A, Berman D. Eat Smart, Live Strong intervention increases fruit and vegetable consumption among low-income older adults. Poster presented at the 2014 Society for Nutrition Education and Behavior Conference; July 2014. Milwaukee, WI. [abstract] J Nutr Educ Behav. 2014 Jul; 46(4):S103-4. doi: 10.1016/j.jneb.2014.04.025
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Anderson DW, Calingaert B. Changes in meat and poultry nutrition labeling regulations: implications for nutrition educators. J Nutr Educ Behav. 1994 Jan;26(1):15-9. doi: 10.1016/S0022-3182(12)80829-6